Get the Stockscreener App
0.80
0.38%
0.003
Biofrontera Inc stock is traded at $0.80, with a volume of 155.87K.
It is up +0.38% in the last 24 hours and down -4.26% over the past month.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
See More
Previous Close:
$0.797
Open:
$0.79
24h Volume:
155.87K
Relative Volume:
0.71
Market Cap:
$9.20M
Revenue:
$39.19M
Net Income/Loss:
$-16.59M
P/E Ratio:
-0.3666
EPS:
-2.182
Net Cash Flow:
$-9.39M
1W Performance:
+11.11%
1M Performance:
-4.26%
6M Performance:
+14.29%
1Y Performance:
-29.20%
1-Day Range:
$0.76
$0.8191
1-Week Range:
$0.5547
$0.853
52-Week Range:
$0.536
$1.87
Biofrontera Inc Stock (BFRI) Company Profile
Name
Biofrontera Inc
Sector
Phone
781-245-1325
Address
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.79 | 9.28M | 39.19M | -16.59M | -9.39M | -2.182 |
|
ZTS
Zoetis Inc
|
129.54 | 57.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.79 | 49.57B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.26 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.12 | 35.57B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
504.81 | 21.08B | 3.08B | 1.24B | 1.07B | 25.61 |
Biofrontera Inc Stock (BFRI) Latest News
Biofrontera completes transfer of Ameluz, RhodoLED FDA approval - MSN
Guidance Update: Can Biofrontera Inc Equity Warrant stock maintain growth trajectoryWeekly Earnings Recap & Growth Oriented Trading Recommendations - moha.gov.vn
Retail Trends: Will Biofrontera Inc. stock split again soonJuly 2025 Summary & Weekly Top Gainers Alerts - Улправда
Is Biofrontera Inc. stock a top momentum playMarket Risk Report & Expert Verified Movement Alerts - Улправда
Will Biofrontera Inc. stock split again soonMarket Activity Report & Accurate Trade Setup Notifications - Улправда
How Biofrontera Inc. Equity Warrant stock benefits from tech adoption2025 Dividend Review & Daily Profit Maximizing Tips - Улправда
How interest rate cuts could boost Biofrontera Inc. Equity Warrant stockGlobal Markets & AI Driven Stock Reports - Улправда
Will Biofrontera Inc. stock reach all time highs in 2025Profit Target & Long Hold Capital Preservation Plans - Улправда
Why Biofrontera Inc. stock remains resilientInflation Watch & Verified Swing Trading Watchlists - Улправда
Can Biofrontera Inc. Equity Warrant stock maintain growth trajectory2025 Support & Resistance & Reliable Momentum Entry Alerts - DonanımHaber
Will Biofrontera Inc. stock outperform Nasdaq indexWeekly Stock Analysis & Free Weekly Chart Analysis and Trade Guides - DonanımHaber
Biofrontera completes transfer of FDA approvals for Ameluz and RhodoLED By Investing.com - Investing.com South Africa
How Biofrontera Inc. stock reacts to global recession fearsGold Moves & Expert Curated Trade Setups - Улправда
Biofrontera completes transfer of FDA approvals for Ameluz and RhodoLED - Investing.com
Biofrontera completes transfer of Ameluz® and Rhodoled® FDA approval - marketscreener.com
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio - The Manila Times
Biofrontera Inc. Completes Transfer of Ameluz® and - GlobeNewswire
Book value per share of Biofrontera Inc. Warrant 2021-27.10.26 on Biofrontera – NASDAQ:BFRIW - TradingView — Track All Markets
Aug Levels: Will Biofrontera Inc Equity Warrant stock split attract more investorsPortfolio Performance Summary & AI Enhanced Trading Alerts - moha.gov.vn
What analysts say about Biofrontera Inc AI10 stockContrarian Investment Ideas & Free Daily Top Stock Picks for All Investors - earlytimes.in
Biofrontera (NASDAQ:BFRI) Trading Down 1.5% – Time to Sell? - Defense World
Biofrontera Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Biofrontera completes phase 1 study for expanded Ameluz treatment areas By Investing.com - Investing.com Nigeria
Will Biofrontera Inc. (AI10) stock sustain bullish trend into 2025Market Growth Review & Risk Controlled Swing Alerts - Newser
Why Biofrontera Inc. (AI10) stock attracts HNW investors2025 Big Picture & Safe Entry Momentum Tips - Newser
Why Biofrontera Inc. (AI10) stock is favored by hedge fundsWeekly Trade Analysis & Daily Oversold Stock Bounce Ideas - Newser
Will Biofrontera Inc. Equity Warrant stock outperform growth indexes2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - Newser
Biofrontera completes final patient visit in Phase 1 PK study of Ameluz gel - TipRanks
Biofrontera completes phase 1 study for expanded Ameluz treatment areas - Investing.com
Biofrontera (Nasdaq: BFRI) wraps Ameluz Phase 1 PK trial on trunk, plans 2026 FDA sNDA - Stock Titan
Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC - MSN
Can Biofrontera Inc. (AI10) stock survive global slowdownJuly 2025 Update & High Yield Stock Recommendations - Newser
Why Biofrontera Inc. stock remains on buy listsWatch List & Long Hold Capital Preservation Plans - Newser
Biofrontera Inc. (BFRI) 5.8% in After-hours: Filing for New Drug Application Boosts Stock - Stocks Telegraph
Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera Inc. (BFRI) 20.51% in After-hours: Notable Price Surge - Stocks Telegraph
Biofrontera submits sNDA to FDA for skin cancer treatment - Investing.com
Biofrontera Inc. announces filing of supplemental new drug application - marketscreener.com
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - The Manila Times
Biofrontera Inc. Announces Filing of Supplemental New Drug - GlobeNewswire
Why global investors buy Biofrontera Inc. (AI10) stockJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
Biofrontera Inc Stock (BFRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):